Latest from Fox Chase

Elizabeth Plimack, MD, discusses updated data from the pivotal CheckMate-025 trial, which compared the use of nivolumab with everolimus in the treatment of patients with metastatic renal cell carcinoma.
Hossein Borghaei, DO, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses how physicians can help patients with lung cancer feel more comfortable reporting adverse events (AEs) associated with immunotherapy.
Lori Rink, PhD, discusses the groundbreaking impact of imatinib (Gleevec) in gastrointestinal stromal tumors, the heterogeneity of the disease and its impact on personalizing treatment, and emerging therapies in the field.
Hossein Borghaei, DO, provides additional insight on checkpoint inhibitors, determining patient selection, and how these therapies will continue to significantly impact the treatment landscape in non–small cell lung cancer for years to come.
Elizabeth Plimack, MD, discusses some of the most impressive advancements with immunotherapy agents in the fields of renal cell carcinoma and bladder cancer, as well as remaining questions with the use of these treatments.
Mohammed Haseebuddin, MD, a fellow in Urologic Oncology at Fox Chase Cancer Center, discusses the overall significance of a study examining an elevated preoperative classical monocyte PD-1 mean fluorescence intensity level in patients with clear cell renal cell carcinoma.
Thomas M. Churilla, MD, Department of Radiation Oncology, Fox Chase Cancer Center, discusses a study exploring the impact of health insurance status on the presentation, local management, and outcomes of patients with head and neck cancer.
Ranee Mehra, MD, discusses what the KEYNOTE-012 findings could mean for patients, the growing role for the immunotherapy agent in head and neck cancer, and what else is on the horizon for the treatment landscape.
Publication Bottom Border
Border Publication